NEW YORK, Oct. 25 /PRNewswire/ -- See video from Novartis:
New Phase III data indicate that Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) demonstrated robust immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease 1, 3. These data were presented during an oral presentation at the 48th annual meeting of the Infectious Disease Society of America (IDSA) held in Vancouver, Canada. Available media includes video and stills.
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE and ZDF.
Registered journalists can access video, audio, text, graphics and photos at http://www.thenewsmarket.com
If you are not already registered, please take a moment to sign up - registration is quick and free: http://www.thenewsmarket.com/registration
SOURCE thenewsmarket.com; Novartis